Cassava Sciences Inc (SAVA)

NASDAQ
50.16
+0.47(+0.95%)
Pre Market
52.15
+1.99(+3.97%)
- Real-time Data
  • Volume:
    3,309,105
  • Bid/Ask:
    49.80/52.60
  • Day's Range:
    49.16 - 52.64

SAVA Overview

Prev. Close
49.69
Day's Range
49.16-52.64
Revenue
-
Open
49.99
52 wk Range
6.7-144.2
EPS
-0.37
Volume
3,309,105
Market Cap
2.01B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
8,283,052
P/E Ratio
-
Beta
0.66
1-Year Change
378.63%
Shares Outstanding
40,014,695
Next Earnings Date
02 Nov 2021
What is your sentiment on Cassava Sciences Inc?
or
Market is currently closed. Voting is open during market hours.

Cassava Sciences Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellBuy
SummaryStrong SellStrong SellStrong SellStrong SellBuy

Cassava Sciences Inc Company Profile

Cassava Sciences Inc Company Profile

Employees
11

Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimers disease. The Company’s products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimers brain. The SavaDx, is an early-stage program focused on detecting the presence of Alzheimers disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is also developing SavaDx is a quantitative blood-based investigational biomarker/diagnostic to detect and monitor Alzheimer's disease. The Company’s scientific approach for the treatment of Alzheimers disease seeks to simultaneously progress both neurodegeneration and neuroinflammation.

Read More
  • Enough of downs. 🚀
    0
    • Remeber not to short 🤭
      0
      • Short more and get squeezed 😆😆
        0
    • Interesting, healthy retracement to 🚀
      0
      • The rise 🚀 will be to the west moon of 180 miles. Your choice not to close shorts 🥳
        0
        • fly to the moon!!!!
          0
          • 🚀🚀🚀🚀🚀🚀🌕
            0
          • Half way to go!! 123.456789 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🌕
            0
          • Midday BB hedge too much. Come on, convert to buy, u make much more.
            0
        • Alright 🚀🚀🚀🚀🚀🚀🚀🚀
          0
          • Autopilot once hit 67. Hedges dont control 💪🏻😁🤣🤣🤣
            0
        • please buy SAVA. good stocks with good track records
          0
          • Better cover shorts 🚀🚀🚀🚀🚀
            0
        • For the rest of you who have not converted your shorts, pls buy back double while u still have the capability. The opportunity is now. If 123.456789 dont motivate u, what can?
          0
          • Better cover shorts 🚀🚀🚀
            0
            • Dear all who have not covered shorts, come on, its not too late, cover and buy more now 🚀 to 123.45678 together
              0
              • U have the capability, opportunity now to switch sides now. The excitement is you double your winning at $120k. Come on buddies!
                0
                • People who short, here js your oppprtunity to switch side before its too late.
                  0
                  • Data have shown the magnificent effects of SAVA. May i invite people who short to buy back double to 🚀🚀 to 123.456789 before its too late. 👌🏻
                    0
                    • Is it taking off??🚀🚀 +12% in pre-market
                      0
                      • That is a big no 🙃
                        0
                    • Seriously, why would SAVA manipulate data? In the long run, if the drugs are not effective, its not going to earn any money. I have full faith in SAVA and FDA
                      0
                      • I think no eyes to see already, have cut from 100. 🖕🏻
                        0
                      • CASSAVA CeO, u never do enough to take care of investors. Shouldnt u buy back and give investors confidence. U s**ks
                        0
                    • I think there should be a limit on how you short. People who contra close to 120 will suicide
                      2
                      • Shortists, pls have mercy on longist 🏳️
                        2
                        • Anyone knows if the FDA accepted the claim and in such case how long it takes to resolve it? I think they plan to start phase 3 trials next month
                          0
                          • dun think fda will accept the claim
                            1
                        • Shortist friends, pls buy back double and we prosperous together at 98. Then 104, and 120 🤑🤑🤑🤑
                          1
                          • Cassava clarification is valid and FDA being very strict should not be wrong. Rebound today 🏀
                            0
                            • another short attack full of false claims from biib.
                              0
                              • In trouble again. Will SAVA go back to 66?
                                1
                                • sava is a hold. big potential!
                                  0
                                  • Thank you Market makers, ive cut loss at less loss for SAVA. Pls help me with AMC. Still stuck at 50.
                                    1
                                    • Need the money back for monthly expenses 🧲
                                      0
                                  • The 9 months results are promising. Market makers, you have scared too many people to manipulate down 🧲
                                    1
                                    • Can u rise back to $100 for me to escape unhurt pls 🙏🏻
                                      0
                                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.